Penzymes Overview

  • Status
  • Private

Penzymes General Information


Developer of Selective Intracrine Modulators (SIMs) designed for the treatment of cancer. The company develops Selective Intracrine Modulators to block the local formation of steroid hormones in hormone-dependent malignancies of the prostate, breast, and endometrium, benefitting patients with castration-resistant prostate cancer (CRPC).

Contact Information

Ownership Status
Privately Held (no backing)
Financing Status
Primary Industry
Other Industries
Outcome Management (Healthcare)
Primary Office
  • 3160 Chestnut Street
  • Suite 200
  • Philadelphia, PA 19104
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Penzymes Executive Team (1)

Name Title Board Seat Contact Info
Trevor Penning Ph.D Founder
To view Penzymes’s complete executive team members history, request access »